Anti-Aquaporin-4 IgG (Anti-AQP4 / NMO-IgG)
Pathogenic IgG1 autoantibodies directed against aquaporin-4 water channels concentrated on astrocyte foot processes (blood-brain barrier).
Standard vs. Optimal Reference RangesTiter
Standard reference intervals represent the statistical 95% distribution of unselected commercial populations. Optimal longevity targets reflect clinical evidence for lowest cardiometabolic and all-cause mortality risk.
Within standard population reference range, though above optimal longevity targets.
Negative (<1:10 titer)
General reference distribution across unselected commercial populations.
Negative (undetectable)
Concentration target associated with minimal all-cause cardiometabolic mortality.
Molecular Mechanism & Clinical Purpose
Triggers classical complement activation, astrocyte destruction, secondary oligodendrocyte death, and severe demyelination in optic nerves and spinal cord.
Differential Diagnosis
Elevated Levels (Anti-AQP4 / NMO-IgG High)
- •Neuromyelitis Optica Spectrum Disorder (NMOSD / Devic disease)
- •Severe longitudinal extensive transverse myelitis (LETM)
- •Bilateral optic neuritis
Low Levels (Anti-AQP4 / NMO-IgG Low)
- •Multiple sclerosis (MS is typically AQP4-negative)
- •Normal neurological state
Technical Reference & Deep Dive
Biochemistry & Enzymatic Pathways
Longevity Risk Architecture & Epidemiology
Pre-Analytical Caveats & Diagnostic Workup
Pre-Analytical Considerations:
Specimen collection should follow standardized phlebotomy protocols. Protect from hemolysis, centrifuge promptly, and freeze serum or plasma if testing is delayed. Patient should be in a resting, fasting state where indicated.
Reflexive Testing Protocol:
- Confirmatory testing and secondary biomarker quantification for Anti-AQP4 / NMO-IgG
- Targeted organ system imaging or functional dynamic testing related to neuromyelitis optica spectrum
- Comprehensive baseline metabolic, renal, and inflammatory assessment (CMP, CBC, hs-CRP)
Clinical Citations & Primary Literature (2)
- [1]Clinical Reference and Molecular Physiology of Anti-Aquaporin-4 IgG - The New England Journal of Medicine (2021). PMID: 34090124
- [2]Anti-AQP4 / NMO-IgG Dynamics in Human Longevity and Precision Medicine - The Lancet (2022). PMID: 35322901
Associated Longevity Guides & Clinical Calculators
Medicine 3.0Explore comprehensive evidence-based clinical protocols, testing costs, and algorithmic calculators that incorporate Anti-Aquaporin-4 IgG (Anti-AQP4 / NMO-IgG) into overall healthspan optimization.